Studies have also shown that OX40-specific agonists can improve immunotherapeutic response rates in PCa patients by using T cell co-stimulation to induce T cell activation and anti-tumor immunity (Sturgill et al., 2021). The gene discussed is TNFRSF4; the disease is neoplasm.